브이티브이 테라퓨틱스(VTVT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $31.80 (+1.27%), 시가총액 $0.14B, 52주 최저~최고 $14.00 ~ $42.72.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point,
브이티브이 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
브이티브이 테라퓨틱스의 현재 주가는 $31.80 (+1.27%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
브이티브이 테라퓨틱스의 시가총액은 약 $0.14B입니다.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its l